Cargando…
Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus
BACKGROUND: COVID-19 pandemic has changed the approach of dermatologists, with respect to management of numerous conditions, vitiligo being one of them. However, there is a lack of consensus on how to deal with patients of vitiligo, as we battle this pandemic. AIM: To conduct a questionnaire-based s...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751686/ https://www.ncbi.nlm.nih.gov/pubmed/35068501 http://dx.doi.org/10.4103/ijd.ijd_859_20 |
_version_ | 1784631728874192896 |
---|---|
author | Chatterjee, Manas Das, Anupam |
author_facet | Chatterjee, Manas Das, Anupam |
author_sort | Chatterjee, Manas |
collection | PubMed |
description | BACKGROUND: COVID-19 pandemic has changed the approach of dermatologists, with respect to management of numerous conditions, vitiligo being one of them. However, there is a lack of consensus on how to deal with patients of vitiligo, as we battle this pandemic. AIM: To conduct a questionnaire-based survey, amongst expert dermatologists; in order to understand the impact of COVID-19 on the management of vitiligo. MATERIALS AND METHODS: An online semi-structured English questionnaire was prepared and the link was circulated among 50 pan-Indian expert dermatologists, through various platforms (snowball sampling). Confidentiality and anonymity were strictly maintained. Responses were analyzed at the end of the study and a consensus statement was generated. RESULTS: 42.22% of the respondents believed that teleconsultation is adequate for the diagnosis and management of most cases of vitiligo. 64.44% were found to be comfortable in prescribing oral medications, even during the COVID-19 pandemic; of which 62% would prefer to prescribe systemic steroids; followed by 17%, 11%, 7%, and 3% who would prefer cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate, respectively. 64.44% respondents would recommend phototherapy in their office and 80% would prefer home-based phototherapy (PUVAsol or handheld NBUVB devices). 86.67% would prefer to stop the oral immunosuppressive drugs, till the COVID-19 RTPCR positive patients are tested negative. LIMITATIONS: The results are based on a survey of a small albeit selected group of dermatologists who decided on the currently available information on COVID-19. The same may change depending on the nature of further available information on the virus and its effect on how we manage the patients. CONCLUSIONS: Cases for initial consultation may be seen physically, and those for follow-up may be scheduled for teleconsultation. Topical therapy may be used without any hesitation. Phototherapy may be best advised with either PUVAsol or home-based phototherapy units (handheld NBUVB devices). With regards to systemic immunosuppressives, oral minipulse therapy may be preferable in view of lesser requirement of monitoring. Surgery for vitiligo should be performed only if the psychological well-being is severely affected. |
format | Online Article Text |
id | pubmed-8751686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-87516862022-01-21 Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus Chatterjee, Manas Das, Anupam Indian J Dermatol Original Article BACKGROUND: COVID-19 pandemic has changed the approach of dermatologists, with respect to management of numerous conditions, vitiligo being one of them. However, there is a lack of consensus on how to deal with patients of vitiligo, as we battle this pandemic. AIM: To conduct a questionnaire-based survey, amongst expert dermatologists; in order to understand the impact of COVID-19 on the management of vitiligo. MATERIALS AND METHODS: An online semi-structured English questionnaire was prepared and the link was circulated among 50 pan-Indian expert dermatologists, through various platforms (snowball sampling). Confidentiality and anonymity were strictly maintained. Responses were analyzed at the end of the study and a consensus statement was generated. RESULTS: 42.22% of the respondents believed that teleconsultation is adequate for the diagnosis and management of most cases of vitiligo. 64.44% were found to be comfortable in prescribing oral medications, even during the COVID-19 pandemic; of which 62% would prefer to prescribe systemic steroids; followed by 17%, 11%, 7%, and 3% who would prefer cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate, respectively. 64.44% respondents would recommend phototherapy in their office and 80% would prefer home-based phototherapy (PUVAsol or handheld NBUVB devices). 86.67% would prefer to stop the oral immunosuppressive drugs, till the COVID-19 RTPCR positive patients are tested negative. LIMITATIONS: The results are based on a survey of a small albeit selected group of dermatologists who decided on the currently available information on COVID-19. The same may change depending on the nature of further available information on the virus and its effect on how we manage the patients. CONCLUSIONS: Cases for initial consultation may be seen physically, and those for follow-up may be scheduled for teleconsultation. Topical therapy may be used without any hesitation. Phototherapy may be best advised with either PUVAsol or home-based phototherapy units (handheld NBUVB devices). With regards to systemic immunosuppressives, oral minipulse therapy may be preferable in view of lesser requirement of monitoring. Surgery for vitiligo should be performed only if the psychological well-being is severely affected. Wolters Kluwer - Medknow 2021 /pmc/articles/PMC8751686/ /pubmed/35068501 http://dx.doi.org/10.4103/ijd.ijd_859_20 Text en Copyright: © 2021 Indian Journal of Dermatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Chatterjee, Manas Das, Anupam Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus |
title | Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus |
title_full | Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus |
title_fullStr | Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus |
title_full_unstemmed | Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus |
title_short | Management of Vitiligo Amidst the COVID-19 Pandemic: A Survey and Resulting Consensus |
title_sort | management of vitiligo amidst the covid-19 pandemic: a survey and resulting consensus |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751686/ https://www.ncbi.nlm.nih.gov/pubmed/35068501 http://dx.doi.org/10.4103/ijd.ijd_859_20 |
work_keys_str_mv | AT chatterjeemanas managementofvitiligoamidstthecovid19pandemicasurveyandresultingconsensus AT dasanupam managementofvitiligoamidstthecovid19pandemicasurveyandresultingconsensus |